NORD Announces Request for Applications to Implement Two New Patient Registries on IAMRARE® Platform with Support from Critical Path Institute

NORWELL, Mass. — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two additional patient registries on its proprietary NORD® IAMRARE® platform. This significant expansion of rare disease data collection infrastructure is made possible through critical funding provided by the Rare Disease Cures Accelerator—Data and Analytics Platform (RDCA-DAP®), a collaborative initiative with the Critical Path Institute that is funded by the U.S. Food and Drug Administration (FDA).

The announcement marks another milestone in the ongoing effort to empower rare disease patient communities by providing them with the tools, technological infrastructure, and institutional support needed to gather comprehensive, standardized patient-reported data. By leveraging the IAMRARE platform, successful applicant organizations will be equipped to systematically collect natural history data and patient experiences, which are widely recognized as vital components in accelerating medical research and therapeutic development for underserved patient populations.

Tracey Sikora, Vice President of Research and Clinical Programs at NORD, emphasized the profound impact that community-led research studies have consistently demonstrated over the years. This new funding opportunity directly builds upon NORD’s extensive, long-standing body of work supporting rare disease nonprofits and patient advocacy organizations in their scientific endeavors.

"This opportunity builds on NORD’s work supporting rare disease nonprofits," says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. "Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval."

The tangible successes of previous IAMRARE registries highlight the transformative potential of patient-centered data collection. When rare disease communities take an active role in gathering and structuring real-world evidence, they bridge critical knowledge gaps that often hinder academic researchers and biopharmaceutical developers. The ability of these registries to directly inform regulatory milestones, such as clinical outcome assessments and formal FDA approvals, underscores their immense value within the broader clinical development ecosystem.

Under the terms of the newly announced initiative, successful applicants will begin working closely with NORD starting in April 2027. The primary objective of this collaboration is to successfully create, customize, and launch a dedicated patient registry tailored specifically to the unique needs of their respective rare disease community.

Throughout the implementation phase, NORD will handle the foundational technical requirements by building and hosting the registry website. Beyond the technical deployment, NORD will provide comprehensive training and guidance to the registry sponsors. This hands-on support encompasses a wide array of operational milestones, including establishing a dedicated registry advisory board, developing a robust study protocol, building and customizing patient surveys, navigating the complex Institutional Review Board (IRB) process, and determining clear, ethical criteria for sharing the collected data with qualified researchers.

Application Criteria

Applicants seeking to secure this unique implementation opportunity must meet specific organizational and operational criteria established by NORD and its program partners. These requirements ensure that selected patient advocacy groups are fully prepared to manage the ongoing responsibilities of maintaining a clinical-grade patient registry and engaging their respective patient communities effectively over the long term.

How to Apply

The formal request for applications is officially open, and interested rare disease organizations must submit their application materials before the deadline closes on January 10, 2027. Following the submission window, NORD will review the proposals and notify accepted applicants by February 1, 2027. Preparations and official registry implementation activities are scheduled to officially kick off in April 2027. Eligible organizations interested in submitting a proposal can access the application portal online.

Any questions or inquiries regarding the request for applications process should be directed to NORD’s designated administrative contact via email.

About the NORD® IAMRARE® Platform

The NORD® IAMRARE® Platform serves as a robust, centralized technological infrastructure designed specifically for patient advocacy organizations seeking to capture real-world evidence and patient-reported data securely. To date, the platform proudly hosts more than 55 live registries sponsored by various patient organizations. These registries empower communities to securely collect, manage, and share critical health data to advance scientific understanding and therapeutic discovery. Additional information regarding the platform and its capabilities can be found on its official website.

About the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®)

The Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®) is a prominent FDA-sponsored initiative engineered to provide a centralized and standardized infrastructure. By aggregating rare disease data from diverse sources, RDCA-DAP supports and accelerates rare disease characterization, with the overarching goal of expediting therapy development across the entire medical research sector. Further details concerning the program can be reviewed through the Critical Path Institute’s online resources.

About the National Organization for Rare Disorders (NORD®)

Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan nonprofit organization dedicated to improving the health and lives of more than 30 million Americans affected by rare diseases. Operating in close partnership with more than 350 disease-specific member patient organizations and 49 designated NORD Rare Disease Centers of Excellence spanning over 170 academic medical centers, research institutions, and children’s hospitals nationwide, NORD continually advances care, research, education, and advocacy to create a better future for people and families impacted by rare conditions.

Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders

Jia Lissa

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya